TY  - JOUR

T1  - Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

JO  - The Lancet Oncology

UR  - http://dx.doi.org/10.1016/s1470-2045(23)00460-6

PY  - 2023/11/02

AU  - Velikova G

AU  - Morden JP

AU  - Haviland JS

AU  - Emery C

AU  - Barrett-Lee P

AU  - Earl H

AU  - Bloomfield D

AU  - Brunt AM

AU  - Canney P

AU  - Coleman R

AU  - Verrill M et al

ED  - 

DO  - DOI: 10.1016/s1470-2045(23)00460-6

PB  - Elsevier BV

VL  - 24

IS  - 12

SP  - 1359

EP  - 1374

Y2  - 2025/10/10

ER  -